Ligand Pharmaceuticals (LGND) – Analysts’ Recent Ratings Updates

Ligand Pharmaceuticals (NASDAQ: LGND) has recently received a number of price target changes and ratings updates:

• 8/11/2026 – Ligand Pharmaceuticals was upgraded by Weiss Ratings from “hold (c)” to “buy (b-)”.
• 8/7/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $340.00 to $345.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Ligand Pharmaceuticals had its price target raised by HC Wainwright from $289.00 to $358.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Ligand Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $326.00 price target on the stock, up from $285.00.
• 7/21/2026 – Ligand Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $387.00 price target on the stock.
• 7/15/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $262.00 to $340.00. They now have an “outperform” rating on the stock.
• 7/9/2026 – Ligand Pharmaceuticals had its price target raised by Bank of America Corporation from $266.00 to $388.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Ligand Pharmaceuticals had its price target raised by Stifel Nicolaus from $255.00 to $332.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, Director Jason Haas sold 6,461 shares of the stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $255.58, for a total transaction of $1,651,302.38. Following the completion of the sale, the director owned 4,981 shares in the company, valued at approximately $1,273,043.98. This represents a 56.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John L. Lamattina sold 4,591 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $250.88, for a total value of $1,151,790.08. Following the transaction, the director directly owned 26,969 shares in the company, valued at approximately $6,765,982.72. This represents a 14.55% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 33,197 shares of company stock valued at $8,744,572. 5.60% of the stock is owned by insiders.

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.